Numis Securities Ltd reaffirmed their buy rating on shares of Allergy Therapeutics plc (LON:AGY) in a research note published on Tuesday morning, StockTargetPrices.com reports. Numis Securities Ltd currently has a GBX 37 ($0.48) price target on the stock.
Several other brokerages have also commented on AGY. Panmure Gordon reissued a buy rating and set a GBX 53 ($0.69) price objective on shares of Allergy Therapeutics plc in a report on Friday, June 10th. Stifel Nicolaus reissued a buy rating and set a GBX 72 ($0.94) price objective on shares of Allergy Therapeutics plc in a report on Friday, July 8th.
Shares of Allergy Therapeutics plc (LON:AGY) opened at 20.00 on Tuesday. The firm’s market cap is GBX 111.90 million. The stock’s 50 day moving average is GBX 18.72 and its 200 day moving average is GBX 22.42. Allergy Therapeutics plc has a 12 month low of GBX 17.25 and a 12 month high of GBX 34.82.
In other news, insider Nicolas Wykeman bought 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 27th. The stock was bought at an average price of GBX 18 ($0.23) per share, for a total transaction of £27,000 ($35,243.44). Also, insider Peter Jensen bought 30,000 shares of the company’s stock in a transaction that occurred on Thursday, September 29th. The stock was purchased at an average price of GBX 19 ($0.25) per share, with a total value of £5,700 ($7,440.28).
Allergy Therapeutics plc Company Profile
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.